Department of Internal Medicine, Center of Medical Sciences of Federal University of Pernambuco, Recife, PE, Brazil.
Department of Immunology, Autoimmune Research Institute, Recife, PE, Brazil.
Am J Case Rep. 2021 Aug 1;22:e932531. doi: 10.12659/AJCR.932531.
BACKGROUND Hypercoagulable states, including venous and arterial thromboses, manifesting as pulmonary thromboembolism or stroke have been observed in COVID-19; recently, gastrointestinal thrombotic events have also been reported. This case report describes a patient with COVID-19 and abdominal pain, who developed coagulopathy and a rare association of hepatic artery thrombosis. Common hepatic artery thrombosis is usually observed among liver transplantation patients and has not been described in infectious disease. CASE REPORT A 45-year-old woman presented in the Emergency Department with a nonproductive cough, sore throat, asthenia, headache, myalgia, anosmia, and dysgeusia. On the 5th day after the onset of these symptoms, she tested positive for SARS-COV-2 and was managed with symptomatic drugs. Although her initial symptoms of COVID-19 improved progressively, on the 14th day she experienced acute abdominal pain. On the 16th day, she was hospitalized and administered intravenous analgesia. Abdominal computed tomography angiography revealed partial thrombosis in the common hepatic artery, which was confirmed by liver Doppler ultrasonography. Protein C and D-dimer levels peaked during this period. Serum tests for thrombophilia were negative. Subcutaneous enoxaparin (60 mg twice daily) was administered during hospitalization, and her abdominal pain improved significantly. She was discharged after 3 days and prescribed an oral anticoagulant for the next 30 days. CONCLUSIONS Thrombotic events are well-recognized complications of COVID-19 and recent reports show gastrointestinal involvement. This report of a rare association of hepatic artery thrombosis highlights the importance of investigating the thrombotic events in patients with abdominal pain and coagulopathy during COVID-19.
包括静脉和动脉血栓形成的高凝状态,表现为肺血栓栓塞或中风,在 COVID-19 中已经观察到;最近,也有报道称胃肠道血栓形成事件。本病例报告描述了一例 COVID-19 患者伴腹痛,发生凝血病和罕见的肝动脉血栓形成。肝总动脉血栓形成通常在肝移植患者中观察到,在传染病中尚未描述。
一名 45 岁女性因干咳、咽痛、乏力、头痛、肌痛、嗅觉丧失和味觉障碍到急诊科就诊。在出现这些症状的第 5 天,她的 SARS-COV-2 检测呈阳性,并接受对症药物治疗。尽管她的 COVID-19 初始症状逐渐改善,但在第 14 天,她出现了急性腹痛。第 16 天,她住院并接受静脉内镇痛治疗。腹部计算机断层血管造影显示肝总动脉部分血栓形成,经肝脏多普勒超声检查得到证实。在此期间,蛋白 C 和 D-二聚体水平达到峰值。血栓形成倾向的血清检查为阴性。住院期间给予皮下依诺肝素(每天两次 60mg),腹痛明显改善。她在 3 天后出院,并开了 30 天的口服抗凝药。
血栓形成事件是 COVID-19 的公认并发症,最近的报告显示胃肠道受累。肝总动脉血栓形成的这种罕见关联的报告强调了在 COVID-19 期间对腹痛和凝血病患者进行血栓形成事件调查的重要性。